Taku Fujimura Selected Research

Lymphomatoid Papulosis

1/2022	Nodal anaplastic large cell lymphoma with lymphomatoid papulosis following treatment of initially presumed atopic dermatitis with dupilumab: A case report.
2/2018	Successful control of phototherapy-resistant lymphomatoid papulosis with oral bexarotene.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Taku Fujimura Research Topics

Disease

55	Melanoma (Melanoma, Malignant) 08/2022 - 12/2006
54	Neoplasms (Cancer) 04/2022 - 12/2006
12	Mycosis Fungoides 02/2022 - 01/2006
10	Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous) 02/2022 - 09/2016
9	Squamous Cell Carcinoma (Epidermoid Carcinoma) 10/2020 - 09/2014
5	Neoplasm Metastasis (Metastasis) 09/2021 - 01/2018
5	Lymphoma (Lymphomas) 11/2020 - 01/2004
5	Inflammation (Inflammations) 01/2019 - 11/2005
5	Extramammary Paget Disease (Paget Disease, Extramammary) 01/2019 - 11/2012
4	Skin Neoplasms (Skin Cancer) 04/2022 - 01/2019
4	Pemphigus (Pemphigus Vulgaris) 03/2021 - 09/2013
4	Psoriasis (Pustulosis Palmaris et Plantaris) 03/2021 - 05/2012
4	Bullous Pemphigoid (Pemphigoid) 11/2018 - 01/2014
4	Autoimmune Diseases (Autoimmune Disease) 01/2018 - 09/2012
4	Carcinoma (Carcinomatosis) 01/2017 - 09/2012
3	Skin Diseases (Skin Disease) 01/2022 - 10/2013
3	Fever (Fevers) 01/2021 - 01/2018
3	Sarcoma (Soft Tissue Sarcoma) 09/2020 - 05/2013
3	Carcinogenesis 01/2020 - 09/2018
3	Disease Progression 09/2018 - 01/2016
3	Hemangiosarcoma (Angiosarcoma) 01/2013 - 01/2012
2	Rheumatoid Arthritis 05/2022 - 05/2015
2	Lymphomatoid Papulosis 01/2022 - 02/2018
2	Atopic Dermatitis (Atopic Eczema) 01/2022 - 01/2017
2	Drug Eruptions (Drug Eruption) 01/2022 - 05/2015
2	Lichen Planus (Lichen Ruber Planus) 01/2021 - 10/2019
2	Necrosis 12/2020 - 04/2009
2	T-Cell Lymphoma (Lymphoma, T Cell) 01/2020 - 01/2019
2	Keratoacanthoma 01/2019 - 09/2017
2	Erythema 02/2018 - 09/2012
2	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 01/2018 - 01/2017
2	Dermatofibrosarcoma 01/2017 - 05/2011
2	Fibrosis (Cirrhosis) 01/2017 - 01/2015
2	Merkel Cell Carcinoma 10/2016 - 11/2012
1	Interstitial Nephritis (Tubulointerstitial Nephritis) 05/2022
1	Hypercholesterolemia 02/2022
1	Hypertriglyceridemia 02/2022
1	Neutropenia 02/2022

Drug/Important Bio-Agent (IBA)

32	NivolumabIBA 01/2022 - 01/2016
16	ChemokinesIBA 03/2021 - 11/2015
14	IpilimumabIBA 09/2021 - 09/2016
12	AntibodiesIBA 08/2022 - 09/2017
12	Immune Checkpoint InhibitorsIBA 04/2022 - 05/2017
12	Biomarkers (Surrogate Marker)IBA 01/2021 - 01/2016
10	dabrafenibIBA 05/2022 - 02/2018
10	trametinibIBA 05/2022 - 02/2018
9	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 05/2022 - 09/2017
7	Bexarotene (LGD1069)FDA Link 02/2022 - 01/2017
7	PeriostinIBA 09/2021 - 01/2015
7	pembrolizumabIBA 01/2021 - 01/2018
7	Interleukin-17 (Interleukin 17)IBA 01/2020 - 09/2012
6	CytokinesIBA 01/2020 - 01/2016
6	Therapeutic UsesIBA 01/2020 - 11/2005
5	Proteins (Proteins, Gene)FDA Link 04/2022 - 11/2005
5	RetinoidsIBA 01/2022 - 01/2004
5	mogamulizumabIBA 11/2020 - 01/2018
5	LigandsIBA 11/2020 - 10/2018
4	binimetinibIBA 05/2022 - 06/2020
4	encorafenibIBA 05/2022 - 06/2020
4	Biological ProductsIBA 09/2021 - 05/2015
4	Matrix Metalloproteinases (MMPs)IBA 09/2021 - 11/2012
4	Proto-Oncogene Proteins B-rafIBA 09/2021 - 01/2019
4	InterferonsIBA 01/2021 - 01/2006
4	Denosumab FDA Link 01/2020 - 01/2017
4	Aryl Hydrocarbon Receptors (Aryl Hydrocarbon Receptor)IBA 01/2020 - 01/2017
3	Retinoid X Receptors (Retinoid X Receptor)IBA 01/2022 - 01/2018
3	Messenger RNA (mRNA)IBA 01/2020 - 11/2015
3	Interleukin-23 (Interleukin 23)IBA 01/2020 - 05/2018
3	Programmed Cell Death 1 ReceptorIBA 01/2019 - 01/2018
3	Interleukin-12 (IL 12)IBA 05/2018 - 04/2004
3	RANK LigandIBA 01/2018 - 01/2016
3	PeplomycinIBA 01/2017 - 09/2014
2	Tacrolimus (Prograf)FDA LinkGeneric 01/2022 - 05/2012
2	MAP Kinase Kinase Kinases (MAP Kinase Kinase Kinase)IBA 09/2021 - 09/2019
2	Dacarbazine (DIC)FDA LinkGeneric 09/2020 - 01/2018
2	Etoposide (VP 16)FDA LinkGeneric 01/2020 - 01/2018
2	Histone Deacetylase InhibitorsIBA 09/2019 - 01/2019
2	B7-H1 AntigenIBA 03/2019 - 01/2019
2	Prednisolone (Predate)FDA LinkGeneric 11/2018 - 01/2017
2	Indicators and Reagents (Reagents)IBA 01/2018 - 01/2018
2	Imiquimod (Aldara)FDA LinkGeneric 01/2018 - 01/2017
2	Interferon-gamma (Interferon, gamma)IBA 09/2016 - 01/2004
2	Interferon-alpha (Interferon Alfa)IBA 09/2016 - 04/2007
2	HaptensIBA 06/2016 - 04/2009
2	Interleukin-4 (Interleukin 4)IBA 02/2016 - 04/2004
2	InterleukinsIBA 01/2014 - 04/2009
2	dermcidinIBA 11/2013 - 09/2011
2	Adenosine Triphosphate (ATP)IBA 10/2013 - 04/2009
2	Docetaxel (Taxotere)FDA Link 01/2013 - 01/2012
2	Risedronic Acid (Actonel)FDA LinkGeneric 01/2013 - 01/2012
2	Diphosphonates (Bisphosphonates)IBA 01/2013 - 01/2012
2	SteroidsIBA 09/2012 - 01/2006
2	MucinsIBA 01/2012 - 01/2006
1	Extracellular Matrix ProteinsIBA 04/2022
1	Indomethacin (Indometacin)FDA LinkGeneric 01/2022

Therapy/Procedure

51	Therapeutics 08/2022 - 02/2008
14	Immunotherapy 04/2022 - 11/2005
6	Drug Therapy (Chemotherapy) 02/2021 - 09/2014
5	Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated) 09/2021 - 05/2017
4	Radiotherapy 05/2019 - 01/2012